Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs JetBlue Airways Corporation — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $13.5 (market cap $5.85B), while JetBlue Airways Corporation trades at $3.91 (market cap $1.50B). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 3.9× JetBlue Airways Corporation's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and JetBlue Airways Corporation for 44 Days on average.
| IOVA | JBLU | |
|---|---|---|
Market Cap | $5.85B | $1.50B |
Volume | 14,517,176 | 22,018,927 |
Sector | Health | Industrials |
52-Week High | $14.82 | $6.46 |
52-Week Low | $1.81 | $3.92 |
Typical Hold Time | 0 Days | 44 Days |
Enterprise Value | $5.78B | $8.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JetBlue (JBLU) trades at $3.97, down 1.49% on the day, with the stock showing bearish technical momentum despite trading near its 52-week low. The company continues to face fundamental challenges with negative net income margins (-9.32% in 2025) and declining revenue trends, though valuation metrics like P/S (0.15) and P/B (0.94) appear attractive. Recent developments include route expansion to Colombia and the launch of BlueFirst premium seating, while activist investor Carl Icahn recently exited board positions per the 2024 agreement.
The outlook remains challenging with persistent losses and high debt levels (debt-to-asset ratio over 50%), though analyst consensus targets $5.89 suggesting potential upside. Key risks include elevated fuel costs, competitive pressures, and ongoing negative cash flow from operations. Investment opportunity exists for value investors betting on operational turnaround, but requires careful risk management given the company's financial strain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
